We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cardinal Health's (CAH) Unit to Aid Canadian Healthcare System
Read MoreHide Full Article
Cardinal Health, Inc.’s (CAH - Free Report) wholly owned subsidiary – Cardinal Health Canada – recently announced an employee vaccination requirement policy, which is part of its continued efforts to protect employees, customers and the Canadian Healthcare system against COVID-19.
Taking into consideration the recent and pending provincial government directives and customer protocols in Canada, Cardinal Health Canada aims to have all employees vaccinated by January 2022.
It is worth mentioning that Cardinal Health Canada manufactures and distributes medical and surgical products and offers clinical and supply chain solutions throughout the continuum of healthcare. It lends support to 95% of hospitals, and above 4,000 long-term care, retirement and assisted living homes throughout Canada.
This announcement is likely to provide a boost to Cardinal Health's Pharmaceutical business.
More on the News
Per management at Cardinal Health Canada, vaccination is the most helpful defense to counter the threat of COVID-19 and safeguard broader public health.
Image Source: Zacks Investment Research
Apart from this, Cardinal Health Canada's decision reflects its commitment to not only protect its employees but also cooperate with its healthcare customers and be a responsible employeer in Canada.
Industry Prospects
Per a report by Fortune Business Insights, the global vaccines market was worth $46.88 in 2019 and is anticipated to reach $104.87 billion by 2027, witnessing a CAGR of 10.7% during the forecast period (2020-2027). Hence, this announcement is a well-timed one for Cardinal Health.
Recent Developments
In August, the company partnered with IRE EliT, the radiopharmaceutical subsidiary of IRE Group, to expand patient access to novel radiopharmaceuticals for Positron Emission Tomography (PET) imaging to support the increasing demand for Ga-68 labeled radiopharmaceuticals.
Again, in August, Cardinal Health extended its agreements with CVS Health, wherein the former will distribute pharmaceuticals to retail pharmacies and distribution centers through Jun 30, 2027.
Plus, in the same month, Cardinal Health partnered with Abbott and Quidel to commercialize and expand access to over-the-counter rapid COVID-19 tests.
Price Performance
Shares of this Zacks Rank #5 (Strong Sell) company have gained 12% in a year’s time, compared with the industry’s growth of 31.8%.
Image: Bigstock
Cardinal Health's (CAH) Unit to Aid Canadian Healthcare System
Cardinal Health, Inc.’s (CAH - Free Report) wholly owned subsidiary – Cardinal Health Canada – recently announced an employee vaccination requirement policy, which is part of its continued efforts to protect employees, customers and the Canadian Healthcare system against COVID-19.
Taking into consideration the recent and pending provincial government directives and customer protocols in Canada, Cardinal Health Canada aims to have all employees vaccinated by January 2022.
It is worth mentioning that Cardinal Health Canada manufactures and distributes medical and surgical products and offers clinical and supply chain solutions throughout the continuum of healthcare. It lends support to 95% of hospitals, and above 4,000 long-term care, retirement and assisted living homes throughout Canada.
This announcement is likely to provide a boost to Cardinal Health's Pharmaceutical business.
More on the News
Per management at Cardinal Health Canada, vaccination is the most helpful defense to counter the threat of COVID-19 and safeguard broader public health.
Apart from this, Cardinal Health Canada's decision reflects its commitment to not only protect its employees but also cooperate with its healthcare customers and be a responsible employeer in Canada.
Industry Prospects
Per a report by Fortune Business Insights, the global vaccines market was worth $46.88 in 2019 and is anticipated to reach $104.87 billion by 2027, witnessing a CAGR of 10.7% during the forecast period (2020-2027). Hence, this announcement is a well-timed one for Cardinal Health.
Recent Developments
In August, the company partnered with IRE EliT, the radiopharmaceutical subsidiary of IRE Group, to expand patient access to novel radiopharmaceuticals for Positron Emission Tomography (PET) imaging to support the increasing demand for Ga-68 labeled radiopharmaceuticals.
Again, in August, Cardinal Health extended its agreements with CVS Health, wherein the former will distribute pharmaceuticals to retail pharmacies and distribution centers through Jun 30, 2027.
Plus, in the same month, Cardinal Health partnered with Abbott and Quidel to commercialize and expand access to over-the-counter rapid COVID-19 tests.
Price Performance
Shares of this Zacks Rank #5 (Strong Sell) company have gained 12% in a year’s time, compared with the industry’s growth of 31.8%.
Stocks to Consider
Some better-ranked stocks from the broader medical space are Henry Schein, Inc. (HSIC - Free Report) , Envista Holdings Corporation (NVST - Free Report) and Patterson Companies, Inc. (PDCO - Free Report) , each currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Henry Schein’s long-term earnings growth rate is estimated at 13.9%.
Envista Holdings’ long-term earnings growth rate is estimated at 27.4%.
Patterson Companies’ long-term earnings growth rate is projected at 9.6%.